PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
or the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known bstitute for form 1449/PTO **Application Number** 10/823,447 Filing Date 04/13/2004 INFORMATION DISCLOSURE First Named Inventor Scott Baron STATEMENT BY APPLICANT Art Unit

(Use as many sheets as necessary) **Examiner Name** Attorney Docket Number

Evenines	Cito	Dearment Number	Publication Date	OCUMENTS Name of Patentee or	Donne Columne Lines When		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					
		09-					
		US-					
		US-					
		US-	-				
		US-		•			
		US-			<u> </u>		
		US-					
		US-					
		US-					
	-	US-					
		US-					
:		US-					
		US-					
·		US-					
		US-					
_		US-					
		US-					
		US-			- 		
		US-	 				

		FORE	<u>IGN PATENT DOCU</u>	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	,	Or Relevant Figures Appear	
4re	wo	00/20450				
						L
						L
						Ľ
	ļ					L
	1			(Г

Examiner	1. 111.0	Date 19 M 1	-
Signature	200m	Considered / 5000 6	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Please type	a plus	sign (+	ebiani (this	box	→	+
		0 (,			_	. —

Sheet

of

PTC/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PC20557A

Inc	der the Paper	rwork Reduction Act of	1995	no persons are required to re-	spond to a collection of information unles	s it contains a valid OMB control number.			
d	Substitu	ute for form 1449B/PT0	5		Complete if Known				
. 4	? <u>`</u>				Application Number	10/823,447			
	INF)	ORMATION	N D	ISCLOSURE	Filing Date	April 13, 2004			
4	STA	TEMENT	BY	ISCLOSURE APPLICANT	First Named Inventor	Scott Baron			
ķ	,			, , <u></u> ,, , , , , , , , , , , , , , , , ,	Group Art Unit				
		(use as many s	heet	as necessary)	Examiner Name				
- (Sheet	2	of	4	Attorney Docket Number	PC20557A			

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
ner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(e), volume-issue number(s), publisher, city and/or country where published.							
	McLean MJ et al "Gabapentin as add-on therapy in refratory partial epilepsy" Neurol. 1993;43:2292-2298						
	Field et al "Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity" Br. J. Pharmacol. 2001; 132:1-4	<u> </u>					
	Mauri MC et al "Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium" Clin. Drug invest. 2001;21(3):169-174						
	Takasaki I. et al "Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection" Pharmacol. Exp. Ther. 2001;296(2):270-275						
	Bauer CA and Brozoski TJ "Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model" JARO 2001;2/1:54-64						
	Mathew NT et al "Efficacy of gabapentin in migraine prophylaxis" Headache 2001;41:119-128						
	Loprinzi CL et al "Pilot evaluation of gabapentin for treating hot flashes" Mayo Clin. Proc. 2002;77(11):1159-1163						
	Brown JP and Gee NS "Cloning and deletion mutagenesis of the alpha2delta calcium channel subunit from porcine cerebral cortex" J. Biol. Chem. 1998;273:25458-25465						
	Stefani A et al "The efects of gabapenitn on different ligand-and voltage-gated currents in isolated cortical neurons" Epilepsy Research 2001;43(3)239-238						
	Ng GY et al "Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action" Mol. Pharmacol. 2001;59(1):144-152						
	Wang M et al "Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding" Bioche. J. 1999;342:313-320						
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-essue number(s), publisher, city and/or country where published. McLean MJ et al "Gabapentin as add-on therapy in refratory partial epilepsy" Neurol. 1993;43:2292-2298 Field et al "Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity" Br. J. Pharmacol. 2001; 132:1-4 Mauri MC et al "Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium" Clin. Drug invest. 2001;21(3):169-174 Takasaki I. et al "Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection" Pharmacol. Exp. Ther. 2001;296(2):270-275 Bauer CA and Brozoski TJ "Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model" JARO 2001;271:54-64 Mathew NT et al "Efficacy of gabapentin in migraine prophylaxis" Headache 2001;41:119-128 Loprinzi CL et al "Pilot evaluation of gabapentin for treating hot flashes" Mayo Clin. Proc. 2002;77(11):1159-1163 Brown JP and Gee NS "Cloning and deletion mutagenesis of the alpha2delta calcium channel subunit from porcine cerebral cortex" J. Biol. Chem. 1998;273:25458-25465 Stefani A et al "The efects of gabapenitn on different ligand-and voltage-gated currents in isolated cortical neurons" Epilepsy Research 2001;43(3)239-238 Ng GY et al "Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action" Mol. Pharmacol. 2001;59(1):144-152					

Examiner Signature	On	Date Considered	10-26-08

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

					- 1	_
Please	type a	plus sign (+)	inside	this box	-	4

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449B	/PTO	•	Complete if Known			
		-		Application Number	10/823,447		
INFO	PRMATIC	on dis	CLOSURE	Filing Date	April 13, 2004		
STA'	TEMEN	T BY A	PPLICANT	First Named Inventor	Scott Baron		
•				Group Art Unit			
	(use as mai	ny sheets as	necessary)	Examiner Name			
Sheet	3	of	4	Attorney Docket Number	PC20557A		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Cite No.								
Jul		Brown JP et al "Isolation of the [3H]gabapentin-binding protein/alha2delag Ca2+ channel subunit from procine brain: development of a radioligand binding assay for alpha2delta subunits using [3H]leucine" Anal. Biochem. 1998;255(2):236-243						
1	!	Anantharaman V and Aravind L "Cache-a signaling domain common to animal Ca2+-channel subunits and a class of prokaryotic chemotaxis receptors" Trends Biochem. Sci. 2000;25(11):535-537						
		Bork P and Rohde K "More von Willebrand factor typ A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910						
		Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio Techniques 1999;26:1150-1160						
		ACCESSION: M76559; DEFINITION: Human neuronal DHP-sensitive, voltage-dependent, calcium channel alpha-2b subunit mRNA, complete cds.						
		ACCESSION: U73483; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2a isoform mRNA, complete cds.						
		ACCESSION: U73484; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2b isoform mRNA, complete cds.						
		ACCESSION: U73485; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2c isoform mRNA, complete cds.						
		ACCESSION: U73486; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2d isoform mRNA, complete cds.						
		ACCESSION: U73487; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2e isoform mRNA, complete cds.						
Su	-	ACCESSION: M86621; DEFINITION: Rat dihydropyridine-sesitive L-type calcium channel alpha-2 subunit (CCHL2A) gene, complete cds.	 -					

Examiner Signature	SM	Date Considered	10-26-07

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

						•		
Please	type	8	plus sign	(+)	inside	this box	→	+

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/823,447
INFORMATION DISCLOSURE				Filing Date	April 13, 2004
STA	TEMEN	ΓRY Δ	PPLICANT	First Named Inventor	Scott Baron
• • • • • • • • • • • • • • • • • • • •			LIOAN	Group Art Unit	
(use as many sheets as necessary)			necessary)	Examiner Name	
Sheet	4	of	4	Attorney Docket Number	PC20557A

Examiner Initials	l			
	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
GN	ACCESSION: AF077665; DEFINITION: Sus scrofa voltage-dependent calcium channel alpha-2 delta subunit precursor, mRNA, complete cds.			
			1	
				
			1	
		· · · · · · · · · · · · · · · · · · ·		
			\downarrow	
	L	Solvery Date Considered Lundon	\perp	

1	Examiner	41/10	Date 10-56-53
Į	Signature	7 - 010h	Considered C C C C C C C C C C C C C C C C C C C

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.